Spero Therapeutics SG&A Expense (Quarterly) Trends

Spero Therapeutics Inc (SPRO)

1.42 -0.02 (-1.05%) USD | NASDAQ | Apr 24, 16:00

1.42 0.00 (0.00%) Pre-Market: 20:00

SG&A Expense (Quarterly) Chart

Historical SG&A Expense (Quarterly) Data

View and export this data back to 2016. Upgrade now.

Date	Value
December 31, 2023	6.433M
September 30, 2023	5.708M
June 30, 2023	6.096M
March 31, 2023	7.317M
December 31, 2022	6.495M
September 30, 2022	6.632M
June 30, 2022	8.051M
March 31, 2022	15.30M
December 31, 2021	13.02M
September 30, 2021	11.15M
June 30, 2021	9.229M
March 31, 2021	8.299M
December 31, 2020	7.498M
September 30, 2020	5.309M
June 30, 2020	4.547M

Date	Value
March 31, 2020	4.086M
December 31, 2019	3.785M
September 30, 2019	4.133M
June 30, 2019	3.782M
March 31, 2019	3.888M
December 31, 2018	3.649M
September 30, 2018	3.134M
June 30, 2018	3.06M
March 31, 2018	3.044M
December 31, 2017	2.49M
September 30, 2017	3.653M
June 30, 2017	2.957M
March 31, 2017	1.74M
December 31, 2016	2.218M
September 30, 2016	1.909M

SG&A Expense Definition

SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.

Read full definition.

SG&A Expense (Quarterly) Range, Past 5 Years

3.782M

Minimum

Jun 2019

15.30M

Maximum

Mar 2022

7.204M

Average

6.495M

Median

Dec 2022

SG&A Expense (Quarterly) Benchmarks